End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.43 CNY | -.--% | +1.34% | -23.05% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The firm trades with high earnings multiples: 28.67 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.5 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.05% | 817M | - | ||
-9.19% | 6.67B | B- | ||
+24.75% | 3.7B | B- | ||
-1.11% | 3.21B | B- | ||
+6.08% | 1.52B | - | ||
-15.13% | 1.37B | B | ||
-25.63% | 1.24B | C- | ||
-7.62% | 1.21B | - | ||
-10.84% | 1.17B | - | ||
-.--% | 1.05B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603566 Stock
- Ratings Pulike Biological Engineering, Inc.